Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

Related Articles by Review for PubMed (Select 19597185)

1.

The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.

Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, Yaccoby S.

Blood. 2009 Aug 27;114(9):1803-12. doi: 10.1182/blood-2009-01-201954. Epub 2009 Jul 13.

2.

[Effects of bidirectional EphB4-EphrinB2 signaling on bone remodeling].

Fan WB, Zhao JN, Bao NR.

Zhongguo Gu Shang. 2013 Aug;26(8):705-8. Review. Chinese.

PMID:
24266083
3.

Boning up on ephrin signaling.

Mundy GR, Elefteriou F.

Cell. 2006 Aug 11;126(3):441-3. Review.

4.

Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases.

Matsuo K, Otaki N.

Cell Adh Migr. 2012 Mar-Apr;6(2):148-56. doi: 10.4161/cam.20888. Epub 2012 Mar 1. Review.

5.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

6.
7.

[Myeloma bone disease].

Abe M.

Clin Calcium. 2014 Aug;24(8):1159-68. doi: CliCa140811591168. Review. Japanese.

PMID:
25065867
8.

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Garcia-Gomez A, Sanchez-Guijo F, Del CaƱizo MC, San Miguel JF, Garayoa M.

World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. Review.

9.

Osteoblastogenesis and tumor growth in myeloma.

Yaccoby S.

Leuk Lymphoma. 2010 Feb;51(2):213-20. doi: 10.3109/10428190903503438. Review.

10.

Advances in the understanding of myeloma bone disease and tumour growth.

Yaccoby S.

Br J Haematol. 2010 May;149(3):311-21. doi: 10.1111/j.1365-2141.2010.08141.x. Epub 2010 Mar 11. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk